Dr. Laraib Iqbal, Dr. Lubna Munir, Dr. Attia Bukhari
An estimated 34% of American adults were obese, and an additional 34% were overweight in 2007–2008. Obesity is associated with diabetes, hypertension, hyperlipidemia, stroke, heart disease, respiratory problems, osteoarthritis, and several types of cancer. The basic aim of the study is to analyze the combination of naltrexone with bupropion for weight loss. This cross-sectional study was conducted in Nishtar Hospital, Multan during June 2019 to March 2020. Obesity is associated with alterations in neural signaling. Differences in neural responses to hunger and satiation are documented in obese vs. lean individuals and women appear to exhibit lower cognitive control of brain responses to food stimuli than men. Naltrexone is reformulated as a sustained release (SR) dosage form in this combination product, which has bioequivalent exposure to naltrexone immediate release (IR). Naltrexone/bupropion should be used with caution in patients who are elderly or have moderate or severe renal impairment. It should be avoided in patients with severe hepatic disease. Bupropion reduces short-term food intake in lean and obese rodent models and increases energy expenditure by increasing heat production, although the overall effect of bupropion on body weight in animals is modest. It is concluded that naltrexone/bupropion is an effective agent for weight management. Further studies are necessary to determine the effect of naltrexone/ bupropion on cardiovascular outcomes.